Related Experiment Video
Updated: May 20, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Does dose matter? Effect of two different neoadjuvant protocols in advanced NSCLC
Volker Steger1, Stefanie Veit, Tobias Walker
1Clinic of Thoracic, Cardiac and Vascular Surgery, Tübingen University, Tübingen, Germany.
Background:
For stage III, NSCLC neoadjuvant protocols have been intensified up to full dose protocols but up till now the effect of more intensive protocols in a trimodal setting could not be compared directly because of different selection criteria or experience of involved facilities in different studies or multicenter studies. We analyzed our experience with two different neoadjuvant protocols, consistent selection criteria, and surgical teams over 17-year time period.
Method:
Single-center retrospective study in 159 patients concerning survival, recurrence, and downstaging effect.
Results:
Overall median survival was 32 months, with 26 months for protocol 1, and 35 months for protocol 2, respectively. Hospital mortality was 5%. Log-rank test showed significant difference between the protocols for UICC-downstaging-effect, ypT-stage, ypN-stage, and ypUICC-stage, respectively, but only ypN-stage and ypUICC-stage were significant risk factors for survival using Cox regression.
Conclusion:
The median survival benefit of 9 months is evident but (probably still) not significant. The more aggressive protocol 2 shows a significant better downstaging effect concerning N- and UICC-stage if R0-resection can be achieved. Insofar dose does matter!
Related Concept Videos
Dose Size and Dosing Frequency: Determination Methods
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Dosage Regimens: Designs and Approaches
Bioavailability Study Design: Single Versus Multiple Dose Studies
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...